Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (86)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Drazen, J. M
Right arrow Articles by Lee, T. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drazen, J. M
Right arrow Articles by Lee, T. H
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 56:1054-1070 (2000)
© 2000 The British Council


research-article

Heterogeneity of therapeutic responses in asthma

Jeffrey M Drazen1, Edwin K Silverman1 and Tak H Lee2,

1Department of Medicine, Brigham and Women's Hospital and Harvard Medical School Boston USA
2Department of Respiratory Medicine and Allergy, Guy's, King's and Thomas School of Medicine, Guy's Hospital London, UK

Correspondence to:Prof. TH Lee, Department of Respiratory Medicine and Allergy, 5th floor Thomas Guy House, Guy's Hospital, London SEl 9RT, UK.

Abstract

Asthma is a complex clinical syndrome with multiple genetic and enviromental factors contributing to its phenotypic expression. This aetiological heterogeneity adds to the complexity when addressing variation in the response to antiasthma treatment. Currently, there are three main lines of treatment available: (i)inhaled glucocorticoids which have multiple mechanisms of action; (ii)ß2-agonists which are very effective bronchodilators and act predominantly on airway smooth muscle; and (iii) cysteinyl-leukotriene inhibitors. Analysis of the repeatability (r) of the treatment response, defined as the fraction of the total population variance which results from among-individual differences, shows values of r between 60–80% indicating that a substantial fraction of the variance of the treatment respone could be genetic in nature. Among the sources of variability that could contribute to the observed heterogeneity in the response to treatment are the degree of underlying inflammation, such as in glucocorticoid resistance, and polymorphisms in the genes encoding the durg target, such as ß2-adrenoceptor and 5-lipoxygenase.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
DMMHome page
I. C. Allen
Searching for an improved mouse model of allergic airway disease using dual allergen exposures
Dis. Model. Mech., November 1, 2009; 2(11-12): 519 - 520.
[Full Text] [PDF]


Home page
J Pediatr PsycholHome page
J. Rohan, D. Drotar, K. McNally, M. Schluchter, K. Riekert, P. Vavrek, A. Schmidt, S. Redline, and C. Kercsmar
Adherence to Pediatric Asthma Treatment in Economically Disadvantaged African-American Children and Adolescents: An Application of Growth Curve Analysis
J. Pediatr. Psychol., August 26, 2009; (2009) jsp074v1.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
E. Goleva, L.-b. Li, and D. Y. M. Leung
IFN-{gamma} Reverses IL-2- and IL-4-Mediated T-Cell Steroid Resistance
Am. J. Respir. Cell Mol. Biol., February 1, 2009; 40(2): 223 - 230.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. A. Litonjua, J. Lasky-Su, K. Schneiter, K. G. Tantisira, R. Lazarus, B. Klanderman, J. J. Lima, C. G. Irvin, S. P. Peters, J. P. Hanrahan, et al.
ARG1 Is a Novel Bronchodilator Response Gene: Screening and Replication in Four Asthma Cohorts
Am. J. Respir. Crit. Care Med., October 1, 2008; 178(7): 688 - 694.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
A. Panebra, M. R. Schwarb, C. B. Glinka, and S. B. Liggett
Allele-Specific Binding of Airway Nuclear Extracts to Polymorphic beta2-Adrenergic Receptor 5' Sequence
Am. J. Respir. Cell Mol. Biol., June 1, 2007; 36(6): 654 - 660.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S B Liggett
Genetic variability of the {beta}2 adrenergic receptor and asthma exacerbations.
Thorax, November 1, 2006; 61(11): 925 - 927.
[Full Text] [PDF]


Home page
Eur Respir JHome page
M. Peters-Golden, A. Swern, S. S. Bird, C. M. Hustad, E. Grant, and J. M. Edelman
Influence of body mass index on the response to asthma controller agents.
Eur. Respir. J., March 1, 2006; 27(3): 495 - 503.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. J. Lima, S. Zhang, A. Grant, L. Shao, K. G. Tantisira, H. Allayee, J. Wang, J. Sylvester, J. Holbrook, R. Wise, et al.
Influence of Leukotriene Pathway Polymorphisms on Response to Montelukast in Asthma
Am. J. Respir. Crit. Care Med., February 15, 2006; 173(4): 379 - 385.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. E. Wechsler and E. Israel
How Pharmacogenomics Will Play a Role in the Management of Asthma
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 12 - 18.
[Full Text] [PDF]


Home page
Hum Mol GenetHome page
K. G. Tantisira, K. M. Small, A. A. Litonjua, S. T. Weiss, and S. B. Liggett
Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between {beta}-agonist and corticosteroid pathways
Hum. Mol. Genet., June 15, 2005; 14(12): 1671 - 1677.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. G. Tantisira, E. S. Hwang, B. A. Raby, E. S. Silverman, S. L. Lake, B. G. Richter, S. L. Peng, J. M. Drazen, L. H. Glimcher, and S. T. Weiss
TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids
PNAS, December 28, 2004; 101(52): 18099 - 18104.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
S. T. Weiss, S. L. Lake, E. S. Silverman, E. K. Silverman, B. Richter, J. M. Drazen, and K. G. Tantisira
Asthma Steroid Pharmacogenetics: A Study Strategy to Identify Replicated Treatment Responses
Proceedings of the ATS, December 1, 2004; 1(4): 364 - 367.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
K. G. Tantisira, S. Lake, E. S. Silverman, L. J. Palmer, R. Lazarus, E. K. Silverman, S. B. Liggett, E. W. Gelfand, L. J. Rosenwasser, B. Richter, et al.
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids
Hum. Mol. Genet., July 1, 2004; 13(13): 1353 - 1359.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. Wohlsen, C. Martin, E. Vollmer, D. Branscheid, H. Magnussen, W-M. Becker, U. Lepp, and S. Uhlig
The early allergic response in small airways of human precision-cut lung slices
Eur. Respir. J., June 1, 2003; 21(6): 1024 - 1032.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. N. Serhan, S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R.-L. Moussignac
Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals
J. Exp. Med., October 21, 2002; 196(8): 1025 - 1037.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L. J. Palmer, E. S. Silverman, S. T. Weiss, and J. M. Drazen
Pharmacogenetics of Asthma
Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 861 - 866.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.